Iovance Biotherapeutics Inc (NAS:IOVA)
$ 9.4 0.28 (3.07%) Market Cap: 2.86 Bil Enterprise Value: 2.55 Bil PE Ratio: 0 PB Ratio: 3.70 GF Score: 39/100

Q3 2024 Iovance Biotherapeutics Inc Earnings Call Transcript

Nov 07, 2024 / 09:30PM GMT
Release Date Price: $12.28 (+1.15%)
Operator

Thank you for standby. My name is Mandeep, and I'll be your operator today. I'd like to welcome everyone to the Iovance Third Quarter 2024 Financial results call.

I would now like turn the call over to Sara.

Sara Pellegrino
Iovance Biotherapeutics Inc - Senior Vice President, Investor Relations

Thank you, operator. Good afternoon, and thank you for joining this conference call and webcast to discuss our third quarter and year-to-date 2024 financial results as well as recent corporate and development program updates.

Dr. Fred Vogt, our Interim Chief Executive Officer and President, will provide an introduction and summarize the latest progress with our US commercial launch of Amtagvi including revenue and revenue guidance, patient demand and market access, an update on our global regulatory submissions at a high-level summary of our key pipeline. Dr. Brian Gastman, our Executive Vice President, Medical Affairs, will highlight adoption and demand at authorized treatment centers or ATC as well as our community outreach initiatives to drive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot